Mechanisms of irregular bleeding with hormone therapy: the role of matrix metalloproteinases and their tissue inhibitors

Martha Hickey, M Hickey, Julie Crewe, J Crewe, L. A. Mahoney, Dorota A. Doherty, D A Doherty, Ian S. Fraser, I S Fraser, L A Salamonsen, Lois A. Salamonsen
The Journal of clinical endocrinology and metabolism · 2006 · vol. 91(8) , pp. 3189–3198 · doi:10.1210/jc.2005-2748 · PMID:16684831 · W2014822528
Observational OA: bronze CC0 ⤵ 15 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-10 ⓘ

Combined hormone therapy alters endometrial matrix metalloproteinase and tissue inhibitor balance, with increased TIMP-1 production associated with irregular bleeding episodes in users.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

CONTEXT: Irregular bleeding is common in users of combined hormone therapy (HT) and often leads to invasive and expensive investigations to exclude underlying pathology. The mechanisms of HT-related bleeding are poorly understood. Endometrial matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are believed to regulate bleeding during the normal menstrual cycle and are known to be altered in breakthrough bleeding with progestogen-only contraception. OBJECTIVE: The aim of this study was to determine how HT exposure alters endometrial production of MMP-1, -3, -9, and -14 and their tissue inhibitors TIMP-1, -2, -3, and -4 and to determine the relationship between MMP and TIMP production and bleeding patterns in HT users. Endometrial leukocytes regulating MMP production and activation were also assessed. DESIGN: A prospective observational study was conducted between 2003 and 2005. SETTING AND PATIENTS: The study occurred at a tertiary referral menopause clinic at King Edward Memorial Hospital, Western Australia, and included 25 postmenopausal women not taking HT and 73 women taking combined HT. INTERVENTIONS: Endometrium was obtained during and outside bleeding episodes. MAIN OUTCOME MEASURES: We assessed production of MMP-1, -3, -9, and -14 and their tissue inhibitors TIMP-1, -2, -3, and -4 and their relationship to bleeding patterns in HT users. RESULTS: All MMPs studied, with the exception of MMP-9, were expressed at low levels in postmenopausal endometrium. Increases in both MMP-3 and -9 localization were seen in association with irregular bleeding, but these did not reach statistical significance. Endometrial production of TIMP-1 was significantly increased in association with bleeding. Endometrial leukocytes were not related to bleeding, with the exception of uterine natural killer cells, which were significantly increased during bleeding, as previously published. CONCLUSIONS: Irregular bleeding in HT users is associated with a distinct pattern of MMP and TIMP production that differs from that seen in normal menstrual bleeding and from that seen in contraceptive-related breakthrough bleeding. This suggests that the endometrial balance between MMP and TIMP contributes to vascular breakdown with HT but by a different mechanism than that seen in normal menstruation or in breakthrough bleeding.

My notes (saved in your browser only)

MeSH descriptors

Estrogen Replacement Therapy Matrix Metalloproteinases Tissue Inhibitor of Metalloproteinases Uterine Hemorrhage Biopsy Endometrium Endometrium Endometrium Endometrium Estrogen Replacement Therapy Female Humans Immunohistochemistry Leukocyte Count Matrix Metalloproteinase 1 Matrix Metalloproteinase 1 Matrix Metalloproteinase 3 Matrix Metalloproteinase 3 Matrix Metalloproteinase 9 Matrix Metalloproteinase 9

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (51)

Cited by (15)

Source provenance

openalex
last seen: 2026-05-11T05:01:01.489467+00:00
pubmed
last seen: 2026-10-08T21:03:44.483075+00:00
License: CC0 · commercial use OK